following a full submission assessed under the end-of-life and ultra-orphan medicine process:
brigatinib (Alunbrig®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
Brigatinib was associated with an objective response rate of 56% in a single-arm, open-label, phase II study in patients with ALK-positive NSCLC who had progressed on first-line targeted treatment with crizotinib.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of brigatinib. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- brigatinib (Alunbrig)
- SMC ID:
as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published:
- 10 June 2019